Form 8-K AMICUS THERAPEUTICS, For: Feb 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Amicus Therapeutics (FOLD) PT Lowered to $14 at BofA Securities
February 19, 2025 1:48 PM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $14.00 (from $15.00) while maintaining a Buy rating.
The analyst comments "Amicus Therapeutics (FOLD, Buy, $14 PO) announced FY24 total revenue of $528.3mn (33% y/y), Galafold of $458.2mn (y/y... More
